GlobeNewswire

SolarWinds System Management Updates Sharpen Visibility into Physical and Virtual Infrastructure

Dela

Support added for leading all-flash arrays from Dell EMC, HPE Nimble Storage, INFINIDAT and IBM

New functionality creates clear view of server interactions within business applications

AUSTIN, Texas, March 14, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today announced a pair of product updates that offer broader and deeper performance monitoring capabilities across physical and virtual infrastructures, particularly in hybrid environments. The newest version of SolarWinds®  Storage Resource Monitor (SRM) extends support to a wider range of leading all-flash arrays (AFAs), while the latest update to Server & Application Monitor (SAM) permits deeper visibility into interactions between a set of servers running critical business applications.

"Finding clarity through the haze of complexity is vital to successfully keep today's heterogeneous and distributed IT environments running smoothly," said Christoph Pfister, executive vice president of products, SolarWinds. "With support for more leading-edge storage vendor solutions and deeper visibility into the connection between critical infrastructure resources, our system management updates give IT professionals more powerful tools to overcome complexity and optimize performance in their diverse worlds."

Combined, the two updates arm IT professionals with the broad system management, monitoring, alerting, and reporting functionality needed to optimize performance in hybrid environments, across an even broader mix of systems and vendors.

"The latest versions of SRM and SAM are giving us even more flexibility to deploy new technologies, as well as deeper visibility across our servers and applications," said Jeremy Mayfield, IT director, American Cement Company, a leading cement producer based in Sumterville, Fla. "In particular, the new SRM support for all-flash storage, particularly HPE Nimble, will give us a wider set of options for deploying hyper-converged infrastructure.  The new application dependency capabilities in SAM allow us to see more performance data, enabling us to fix issues more quickly and reduce mean time to repair."

All-Flash Array Support for Mid-Market and Enterprise Customers with Storage Resource Monitor (SRM) 6.6

Built on the SolarWinds Orion® Platform , the latest version of SolarWinds SRM (version 6.6) now supports HPE® Nimble Storage®, Dell® EMC® Unity, INFINIDAT® InfiniBox®, and IBM® AIX® FlashSystem 9000 all-flash arrays (AFAs). With this extended support, SRM 6.6 enables resource monitoring across an even wider mix of infrastructures in multi-vendor environments to meet the needs of an even broader set of customers, particularly mid-sized companies that adopt solutions from HPE Nimble Storage, Dell EMC Unity, INFINIDAT, and IBM. 

SRM's data integration with other SolarWinds products, including Virtualization Manager (VMAN) and Server & Application Monitor (SAM) through the Orion Platform, allows for end-to-end relationship mapping from application and virtualization through storage.

Visualize Critical Application Dependencies with Server & Application Monitor (SAM) 6.6

SolarWinds SAM 6.6 offers end-to-end visibility and performance monitoring of server and applications across multiple data centers, remote locations, or the cloud. This latest update includes application dependency functionality that enables customers to automatically discover network-based relationships, between applications and servers, by correlating communications at the application process level.

IT professionals can leverage the new connection details function, a unique capability to visualize server and network metrics of specific application connections within an environment. This function gives users a fast way to visualize data on metrics such as packet loss, latency, network status, and more, thereby creating the opportunity to reduce time required for identification of root causes of application issues. With the latest enhancements, for example, a customer running a large CRM implementation can explore the dependency between its underlying database servers and associated web servers to pinpoint any performance degradation, or other issues, more efficiently.

SAM 6.6 also features a new SolarWinds Orion Agent for IBM AIX, bringing the company's powerful and affordable monitoring features to customers with IBM AIX-powered systems in their infrastructures.

Pricing and Availability

SolarWinds SRM pricing starts at $2,935* for 25 disks, including the first year of maintenance. SolarWinds SAM pricing starts at $2,995* for 150 monitors, including the first year of maintenance.

For more information, including a downloadable, free 30-day evaluation of SRM or SAM, visit the SolarWinds website , or call 866.530.8100.

*Prices as of March 14, 2018 in US Dollars. Pricing may vary based upon the jurisdiction and applicable currency. Please contact a local SolarWinds sales representative to find pricing specific to your jurisdiction.

Additional Resources

Storage Resource Monitor
Server & Application Monitor

Connect with SolarWinds

About SolarWinds 
SolarWinds provides powerful and affordable IT management software to customers worldwide from Fortune 500® enterprises to small businesses, government agencies and educational institutions. We are committed to focusing exclusively on IT Pros, and strive to eliminate the complexity that they have been forced to accept from traditional enterprise software vendors. Regardless of where the IT asset or user sits, SolarWinds delivers products that are easy to find, buy, use, maintain, and scale while providing the power to address all key areas of the infrastructure from on premises to the Cloud. Our solutions are rooted in our deep connection to our user base, which interacts in our THWACK online community to solve problems, share technology and best practices, and directly participate in our product development process. Learn more today at www.solarwinds.com .

The SolarWinds, SolarWinds & Design, Orion, and THWACK trademarks  are the exclusive property of SolarWinds Worldwide, LLC or its affiliates, are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other SolarWinds trademarks, service marks, and logos may be common law marks or are registered or pending registration. All other trademarks mentioned herein are used for identification purposes only and are trademarks of (and may be registered trademarks) of their respective companies.

© 2018 SolarWinds Worldwide, LLC.  All rights reserved.

MEDIA CONTACTS:
Nicole Fachet                                                                                          
Text100                                                                                                   
Phone: 212.871.3950                                                                              
NicoleF@text100.com                                                                           

Mark Stanton
SolarWinds
Phone: 512.682.9692
pr@solarwinds.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6c5d65ff-4cd6-4cb2-9259-142a824df601




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SolarWinds Worldwide, LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum